Sun Pharmaceutical Industries has reported results for third quarter ended December 31, 2024 (Q3FY25).
The company has reported 63.74% rise in its net profit at Rs 1181.05 crore for Q3FY25 as compared to Rs 721.31 crore for the same quarter in the previous year. Total income of the company increased by 21.54% at Rs 6260.20 crore for Q3FY25 as compared to Rs 5150.55 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 13.61% rise in its net profit at Rs 2917.54 crore for the quarter ended December 31, 2024, as compared to Rs 2568.03 crore for the same quarter in the previous year. Total income of the company increased by 11.96% at Rs 14141.08 crore for Q3FY25 as compared to Rs 12630.90 crore for the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: